Basel – The fine chemicals company SpiroChem has relocated to state-of-the-art facilities in the Rosental area of Basel, offering the company an ideal location to significantly expand its operations. SpiroChem has also strengthened its board of directors.
SpiroChem is a spin-off of the Federal Institute of Technology (ETH) in Zurich, where it was also located until recently. According to a statement, the company is now fully operational at its new facilities in Basel.
“We are excited to announce our move to state-of-the-art facilities in Basel. Our new set-up is ideal for interaction and collaborations with large and small organisations, providing flexibility and speed to solve problems, allowing our clients to focus on effectively designing the drugs of tomorrow,” said CEO Thomas Fessard.
SpiroChem offers new molecules, which are used in the R&D of new medications, and it is now a world leader in this industry, developing innovative solutions for the biotech and pharmaceutical sectors.
“SpiroChem intends to become a key player in Basel’s vibrant, innovation-driven, life science scene, supporting our ambition to increase our portfolio of clients and recruit talented employees to join our growing, cutting-edge company,” said Fessard.
In anticipation of the upcoming growth path, SpiroChem has also strengthened its board of directors with the appointment of Anthony Baxter, who has extensive experience in the pharmaceutical industry.
“His industry experience and network will be invaluable as we continue to grow our portfolio of small, medium, and large pharmaceutical, agrochemical and life science clients worldwide,” added Fessard.